H.A.C Pharma announces the acquisition from Eisai Co., Limited of the European and UK rights to the drug product TARGRETIN®

The French pharmaceutical company H.A.C. Pharma boosts its growth strategy in Europe and strengthens its portfolio of drugs with significant therapeutic added value through the acquisition of the European and UK rights to the hematology specialty product TARGRETIN® (bexarotene) from Eisai Co., Limited.

TARGRETIN®, active ingredient bexarotene, is a cancer medicine used for the treatment of the visible signs on the skin of cutaneous T-cell lymphoma (CTCL). CTCL is a rare type of lymphoma (cancer of the lymph tissue) where some white blood cells (T-cells) grow in the skin. TARGRETIN® is used in patients who have an advanced disease and have had at least one other treatment.

H.A.C. Pharma offers patients a diversified portfolio of essential medicines, orphan drugs and life-saving treatments. The group focuses its efforts in three priority therapeutic areas: onco-hematology, central nervous system and endocrinology.

H.A.C. Pharma is recognized for its support to patients in the diagnosis and understanding of their illness, its treatment and therapeutic compliance. To achieve this, H.A.C. Pharma develops new formulations together with compliance tools and deploys a Medical Science Liaison Team to promote the proper use of its medicines. H.A.C. Pharma also directly manages the continuous supply of its product portfolio and leads a pan-European network of distributors.

Along with the founder and majority shareholder Philippe Bissay, the new management team has implemented an intensive search for product acquisitions and in-licensing to expand its portfolio and footprint in Europe and the UK. Supported by Turenne Santé and BNPP Développement, which acquired a stake in the company in January 2022, H.A.C. Pharma wishes to continue expanding its range of products and territories.

Philippe Bissay, Chairman and CEO of H.A.C. Pharma, declares: “We are honored by Eisai’s Team trust and confidence in H.A.C. Pharma. This major acquisition is the second this year, along with very promising in licensing deals and partnerships with international healthcare companies. It rewards the intensive work of our teams and validates our development strategy in Europe, based on the acquisition of proven molecules and the launch of innovative products under license. It is also the result of a close collaboration with our banks: BNP, Arkéa, Caisse d’Epargne, BPI and our financial partner Eiffel.”

Mounia Chaoui and Sophie Canetos, Turenne Santé, indicate: “We are delighted with this second acquisition. This product strengthens H.A.C. Pharma’s positioning in a therapeutic indication that it knows well. We want to continue and significantly expand H.A.C. Pharma product portfolio.”

Frédéric Connault, BNP PARIBAS Développement, adds: “We are very pleased with this acquisition, a major step in the transformation of H.A.C. Pharma into a key European player in hospital and specialty prescription drugs. We wish to continue our efforts in this direction.”